Fengkou Financial Reporter Lou Hua
Weilan Biology As a listed company in Qingdao, although it is classified as agriculture, forestry, animal husbandry and fishery, its technological content is comparable to semiconductor chip companies. The company currently has 34 full-time doctors and hundreds of masters. The proportion of R&D team members and the proportion of R&D investment in revenue are among the top listed companies.
In July 2021, the subsidiary of Blue Biology was successfully selected as the third batch of specialization and special new "little giant" enterprise list announced by the Ministry of Industry and Information Technology of the People's Republic of China.
It is worth noting that the company’s main product enzyme preparation is also of great significance in terms of ecological protection. According to the company’s calculations, in the first half of this year, the company’s enzyme preparation products in downstream customer applications have reduced carbon dioxide emissions by approximately 97 million tons.
In the field of biotechnology with higher technological content, the first-mover advantage of foreign countries is more obvious. Through more than ten years of accumulation, the young company has been cooperating frequently with world-renowned companies and attracted many top talents to join. Now, it has the strength to break hands with world-renowned companies.
enzyme preparation is the "chip" in the field of industrial biotechnology, and the expression system is the "lithography machine" for manufacturing the chip. The construction of the expression system is the core of the development of microbial production strains and the key to the production of products from the laboratory to large-scale production.
Currently, there are not a few domestic companies that can develop their own expression system for enzyme preparations, such as VTR purchased from abroad. Through continuous large-scale R&D investment, Blue Bio has built four high-efficiency protein expression systems and corresponding large-scale fermentation systems, including Trichoderma reesei, Pichia pastoris , Aspergillus niger , and Bacillus.
While deepening the advantages of feed enzymes, the company also strengthened its expansion in the fields of industry, food, energy, and biocatalysis, continuously developed new products, and broke foreign monopolies in some areas.
Enzyme demand growth is the main reason for performance growth
Blue Bio is mainly engaged in the research and development, production and sales of enzyme preparations, microecological preparations and animal health products.Among them, enzyme preparations include feed enzymes, industrial enzymes, food enzymes, and biocatalytic enzymes.
Feed restriction and resistance reduction drive the growth of demand for alternative antibiotic products and the growth of feed enzyme demand driven by the replacement of corn and soybean meal in feed are the main reasons for the company's performance growth.
In layman's terms, when the price of pork is above 30 yuan, downstream farming companies do not consider the cost of feed and use corn as much as possible. Why is it that corn is not only high in energy, but also the scent of pigs and poultry raised is more recognized by consumers.
Now, the price of pork has fallen by 13 yuan a catty, and the good days for downstream companies to lie down and make money soon become raising one and losing one. On the cost side, I had to think of ways to save points. The technology accumulation of Azure Biology is revealed.
In addition to commonly used corn and soybean meal, the by-products of many crops are rich in protein, such as rapeseed meal, peanut meal, cottonseed meal, sunflower meal, etc., which can be used in feed production, but in the past, feed companies With limited strength and technical level, the processing capacity for raw materials is low. With the improvement of biological fermentation technology level, these by-products, as well as wheat, barley, sorghum, cassava flour, etc., can replace part of soybean meal and corn. This substitution process naturally drives the increase in the demand for feed enzymes. Feed enzymes have the functions of promoting digestion, degradation and replenishment, and at the same time reduce diseases caused by indigestion.
Blue Bio has been continuously researching and accumulating on unconventional raw materials for many years, helping the perfect replacement of feed raw materials. The company's VLAND-PCP customized enzyme solution (precise customization based on the feed enzyme application big data system) platform can effectively solve the problems of digestion, absorption and processing of unconventional raw materials, improve feed conversion efficiency, and enhance the growth performance of livestock and poultry. The platform has been recognized by many major customers, and the recognition continues to increase.
In addition, in order to ensure food safety, my country's feed industry has begun a comprehensive ban on resistance from July 2020, which has brought good development opportunities to the company. The company's VLAND-PCP precise customized enzyme, glucose oxidase , mycotoxin degrading enzyme, lysozyme as the core diversified enzyme solution,Obvious effect on substitution.
The company’s products and services have obvious advantages, which strongly support terminal premiums. The company not only has a forward-looking layout of a number of systematic product portfolio plans for feed prohibition, but also has formed a "replacement of anti-iron" that includes enzymes, probiotics, and plant extracts at the feed end. "Triangle", also provides comprehensive services such as feed quality control, internal and external digestive tract models, to enhance customer stickiness.
The big health industry is ready to take off
Blue Bio has invested in research and development for more than ten years and has achieved fruitful results. Qiao Piyuan, Chief Financial Officer of Blue Bio, said that the company's Nutrition and Health Technology Center has developed several fully self-producing bacteria strains with functions such as improving gastrointestinal digestion, anti-oxidation, anti-infection, anti-diarrhea, degrading cholesterol, and lowering blood sugar.
The next step will be to upgrade and expand the existing "Ejiamei" product series, and "utilize the above strains" to increase new products in cooperation with European probiotic companies.
In addition, the company has developed probiotic strains for external use on the skin that are anti-acne, delay skin aging, enhance hair follicle health, and relieve eczema. These strains will be further developed into cosmetic raw materials, and consumers will see them in terminal skin care products in the near future.
's probiotics industry has carried out specific cooperation with the following foreign companies. In the next step, the company will seek to expand the scope of cooperation with internationally renowned companies. Including but not limited to, the Sundpro series probiotic products have been jointly developed with the Italian dietary supplement company.
cooperated with the Danish Probiotics Company to develop anti-acne probiotic skin care products. This raw material has been successfully developed into CN brand lactic acid bacteria anti-acne series products in cooperation with domestic downstream manufacturers.
Highland barley is the crop with the highest β-glucan content in wheat crops in the world. It is also rich in γ-aminobutyric acid, dietary fiber, amylopectin, etc., with very high nutritional and health value. The company has accumulated many years of scientific research in food enzyme catalysis technology and plant-based fermentation technology, which can smoothly apply this type of technology to the development of high-value barley products.
In March 2021, the company signed an agreement with the world's top 500 ADM company on the high-value utilization project of highland barley.We will make full use of our respective technology and terminal market advantages to carry out joint cooperation on new product development, production technology and application development, so as to realize the development of the entire industrial chain of barley in the food and beverage fields.
Huawei experience can be used for reference
Out of confidence in the company’s future development, the company launched a five-year equity incentive plan during the reporting period. If the exercise conditions are met, the company will be attributable to shareholders of the listed company. The compound growth rate of net profit in the next five years is 18.06%, and the long-term incentive mechanism will enhance the company's core competitiveness.
Every company has an AB side, and Azure Bio can do no exception. The company's scientific and technological strength and the aggressive determination of the company's boss are all optimistic to investors. But the company has been doing to B business since its inception. Although the big health track is broader and has a huge space, it requires a lot of effort in branding and marketing.
The reporter noticed that the company's current health strategy is still focusing on using its own scientific research advantages, cooperating with companies with C-end advantages, combining strong forces, and fighting for the market. But if you never cut into the C-end, it will be more difficult to earn the most profitable piece of profit.
So, how to convert? Who is better to convert? One name that cannot be avoided is Huawei. Huawei has entered the mobile phone track from its communications business, and has become the leader in global mobile phone shipments in a short period of time. Many experiences are worth learning from the company.
After all, the "little Huawei" in the field of enzyme preparations by Blue Bio, like Huawei, is a technology-driven company. At the moment when consumers are becoming more and more rational, technology-driven products are easier to open up than before.
